FDA Inspection 1142696 — Jiangsu Sihuan Bioengineering Pharmaceutical Co., Ltd.
The FDA completed an inspection of Jiangsu Sihuan Bioengineering Pharmaceutical Co., Ltd. on May 21, 2021 in Wuxi. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions were found but do not meet the threshold for regulatory action). Product area: Drugs.
Inspection Details
- Classification
- Voluntary Action Indicated (VAI) (VAI)
- End Date
- May 21, 2021
- Fiscal Year
- 2021
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Wuxi (China)